On February 16, 2010
Bristol-Myers’ Damp Squib: Diabetes Drug Onglyza Nets Only $6M in Q4
When AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) won FDA approval for their new jointly marketed diabetes drug, Onglyza, in July 2009, analysts were bullish. One estimated revenues at $1 billion a year. Six months down the line, however, that’s looking
…
0 Comments